ArticleJournal of thoracic disease2025
Tacrolimus overdosing in lung transplant recipients: clinical manifestations and management.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Graft bile analysis for predicting post-transplant outcomes: A literature review and a protocol for a novel biomarker.World journal of gastrointestinal surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tacrolimus is essential for preventing rejection after lung transplantation, but its narrow therapeutic index and interindividual variability increase the risk of overdose. Despite the frequency of overdose, the clinical impact of tacrolimus overdose remains poorly defined. This study aimed to systematically assess the frequency, severity, and clinical consequences of tacrolimus overdose in lung transplant recipients and to propose a structured management approach. Methods: We conducted a retrospective single-center study involving 61 lung transplant recipients treated between January 2022 and December 2023. Tacrolimus overdose was defined as a trough level ≥15 µg/L, and classified as mild (15-<20 µg/L), moderate (20-<25 µg/L), or severe (≥25 µg/L). We analyzed clinical outcomes, renal function, and complications, with special attention to patients with cystic fibrosis (CF). Results: Tacrolimus overdose occurred in 54 patients (88.5%), with a mean peak level of 22 µg/L (range, 10-39) at a median of 81 days post-transplant. Dose normalization required a mean of 11 days (range, 0-87). Acute kidney injury occurred in 37% of patients (odds ratio: 1.14, 95% confidence interval: 0.19-6.80; P>0.99) and was not statistically associated with overdose. None progressed to end-stage renal disease. All four CF patients experienced recurrent overdoses, including moderate and severe episodes. One patient developed posterior reversible encephalopathy syndrome. C-reactive protein levels were frequently elevated, while gastrointestinal and infectious complications were uncommon. Conclusions: Tacrolimus overdose is common after lung transplantation. Although acute kidney injury was frequently observed, a statistically significant association could not be established in our cohort, particularly given the small sample size. CF patients appeared more vulnerable. Although severe complications are rare, they are clinically relevant. These findings underscore the importance of individualized monitoring and support a novel classification and management algorithm to guide prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.